What is the level of liabilities of Bio-Techne this year?
Bio-Techne has a debt balance of 672.2 M USD this year.
Bio-Techne Liabilities 2024
Bio-Techne Liabilities
672.2 M USD
Bio-Techne Dividend yield
Ticker
TECH
ISIN
US09073M1045
WKN
A12ENG
In 2024, Bio-Techne's total liabilities amounted to 672.2 M USD, a 13.36% difference from the 593 M USD total liabilities in the previous year.
Bio-Techne Aktienanalyse
What does Bio-Techne do?
Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Bio-Techne's Liabilities
Bio-Techne's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Bio-Techne's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Bio-Techne's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Bio-Techne's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Bio-Techne’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Bio-Techne Stock
What were the liabilities of Bio-Techne compared to the previous year?
The liabilities of Bio-Techne have increased by 13.36% increased compared to the previous year.
What are the consequences of high debt for investors of Bio-Techne?
High liabilities can pose a risk for investors of Bio-Techne, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Bio-Techne?
Low liabilities mean that Bio-Techne has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Bio-Techne affect the company?
An increase in liabilities of Bio-Techne can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Bio-Techne affect the company?
A decrease in the liabilities of Bio-Techne can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Bio-Techne?
Some factors that can influence the liabilities of Bio-Techne include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Bio-Techne so important for investors?
The liabilities of Bio-Techne are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Bio-Techne take to modify the liabilities?
To change its liabilities, Bio-Techne can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Bio-Techne pay?
Over the past 12 months, Bio-Techne paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bio-Techne is expected to pay a dividend of 0.56 USD.
What is the dividend yield of Bio-Techne?
The current dividend yield of Bio-Techne is .
When does Bio-Techne pay dividends?
Bio-Techne pays a quarterly dividend. This is distributed in the months of September, December, December, March.
How secure is the dividend of Bio-Techne?
Bio-Techne paid dividends every year for the past 0 years.
What is the dividend of Bio-Techne?
For the upcoming 12 months, dividends amounting to 0.56 USD are expected. This corresponds to a dividend yield of 0.87 %.
In which sector is Bio-Techne located?
Bio-Techne is assigned to the 'Health' sector.
Wann musste ich die Aktien von Bio-Techne kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Bio-Techne from 2/26/2024 amounting to 0.08 USD, you needed to have the stock in your portfolio before the ex-date on 2/9/2024.
When did Bio-Techne pay the last dividend?
The last dividend was paid out on 2/26/2024.
What was the dividend of Bio-Techne in the year 2023?
In the year 2023, Bio-Techne distributed 1.043 USD as dividends.
In which currency does Bio-Techne pay out the dividend?
The dividends of Bio-Techne are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Bio-Techne
Our stock analysis for Bio-Techne Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
